Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,582.25
(
-0.64%
)
US TECH 100
23,609.20
(
-0.79%
)
Dow Jones
45,870.99
(
-0.77%
)
Brent Oil
104.34
(
-2.11%
)
Bitcoin
69,782.15
(
-2.05%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mskatiescarletohara post# 35648

Monday, 10/16/2006 11:47:28 PM

Monday, October 16, 2006 11:47:28 PM

Post# of 257259
>which BP will be next to ante up in this indication? What about SGP, PFE and GSK?<

SGP has its own HCV protease inhibitor (#msg-10744850) and is still hanging on to 40% of peg-interferon sales, so they may think they are set in the hepatitis market.

Other than flu, GSK is the has-been of the antiviral arena. I’m baffled by why they haven’t been more active in HCV.

PFE is a no-show, which is equally baffling.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now